Rheumnow Podcast

DERM on RheumNow (November 2025)

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.
 Features Dr. Jack Cush, Editor at RheumNow.com. 
SHOW NOTES
1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV
2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9
3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs
4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm
5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj
6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1).
8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y
9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025
10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000  https://t.co/o7BaWjS4HB

Tuesday Nite Rheumatology (on 11.25.25)

Replay of RheumNow Live 2025 - Vasculitis
Featuring: 

- Dr. Michael Wechsler: Management of EGPA in 2025
- Dr. Rennie Rhee: Imaging in Vasculitis
- Dr. Richard Conway: Modern Treatment of PMR

Vitamin D and Lupus Outcomes (11.21.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Check out: 
RNL 2026 – Feb 7 8 2026 DFW
RheumNow.live

Tuesday Nite Rheumatology (on 11.18.25)

Replay of RheumNow Live 2025 - Spondyloarthritis
Sponsored by AbbVie

Featuring: 
Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis  
Dr. Jennifer Cather - Progress in Hidradenitis Supprativa
Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis

Treating During Pregnancy (11.14.2025)

TNR 11.11.2025 - Replay of RheumNow Live 2025 - Psoriatic Arthritis

Replay of RheumNow Live 2025 - Psoriatic Arthritis
Sponsored by AbbVie

Featuring: 
Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA?
Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA
Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?

TNR 11.6.2025 - Replay of RheumNow Live 2025 - Rheumatoid Arthritis

Featuring: 
Dr. Jeffrey Curtis:  AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect 
Dr. Una Makris:  Key Considerations When Managing Older Adults with RA
Dr. Bryant England: Who will manage multimorbidity in RA

A JAKi in GCA- Phase 3 Results Through 2 Years

A JAKi in GCA- Phase 3 Results Through 2 Years
Sponsored by AbbVie Medical Affairs + Health Impact 

The Interview (11.7.2025)

ACR 2025 SpA Topic Panel

A focused discussion on updates in spondyloarthritis, including emerging data, treatment strategies, and real-world care considerations. Hear expert perspectives and practical takeaways shaping SpA management today.